Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Rewiring tumour cell-macrophage communication to elicit de novo anti-cancer immunity
EF 2020-21
Résumé
The human immune system, specialized in removing harmful or foreign material from the body, can easily fight off the common cold yet fails to eliminate many cancers. This is because tumor cells have evolved mechanisms to suppress or evade recognition by the immune system. For example, tumor cells display cell-surface proteins which act as ""don't-eat-me"" signals to inhibit clearance by immune cells that normally ingest dying or diseased cells. This in turn stops the full recruitment and activation of downstream immune responses against the tumor cells. To combat this mechanism, I will synthesize a therapeutic molecule that combines an inhibitor of the ""don't-eat-me"" signal with a pathogen-associated molecule. Binding of this therapeutic to the tumor cell will block its ""don't-eat-me"" signals and simultaneously display the pathogen-associated molecule on the tumor cell surface, providing ""danger signals"" to promote ingestion by immune cells. In this proposal, I aim to evaluate the extent to which this strategy will enhance tumor cell clearance by immune cells and its impacts on downstream immune activation. I hypothesize that enhancing the ability of certain immune cells to ingest tumor cells can lead to the development of a ""cancer vaccine"". Compared to similar approaches for cancer vaccination, I believe that my strategy will improve therapeutic benefit due to an increase in the perceived ""danger-level"" by the immune system via the ""danger signal"". My research lays the foundation for future investigations in animal models and will deepen our understanding for the impacts of modulating ""danger-levels"" in immune cell ingestion and activation processes. Looking forward, I hope this research will improve patient outcomes and culminate in an off-the-shelf cancer vaccine.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449728
Name
Tseng Chung Yi
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Rewiring tumour cell-macrophage communication to elicit de novo anti-cancer immunity
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibody Engineering; Cancer Vaccine; Cd47 Blockade; Co-Culture Model; Cpg Adjuvant; Flow Cytometry; Immune Checkpoint Blockade; Immunogenic Phagocytosis; Macrophages; Pro-Inflammatory Cytokines
Abstract
The human immune system, specialized in removing harmful or foreign material from the body, can easily fight off the common cold yet fails to eliminate many cancers. This is because tumor cells have evolved mechanisms to suppress or evade recognition by the immune system. For example, tumor cells display cell-surface proteins which act as ""don't-eat-me"" signals to inhibit clearance by immune cells that normally ingest dying or diseased cells. This in turn stops the full recruitment and activation of downstream immune responses against the tumor cells. To combat this mechanism, I will synthesize a therapeutic molecule that combines an inhibitor of the ""don't-eat-me"" signal with a pathogen-associated molecule. Binding of this therapeutic to the tumor cell will block its ""don't-eat-me"" signals and simultaneously display the pathogen-associated molecule on the tumor cell surface, providing ""danger signals"" to promote ingestion by immune cells. In this proposal, I aim to evaluate the extent to which this strategy will enhance tumor cell clearance by immune cells and its impacts on downstream immune activation. I hypothesize that enhancing the ability of certain immune cells to ingest tumor cells can lead to the development of a ""cancer vaccine"". Compared to similar approaches for cancer vaccination, I believe that my strategy will improve therapeutic benefit due to an increase in the perceived ""danger-level"" by the immune system via the ""danger signal"". My research lays the foundation for future investigations in animal models and will deepen our understanding for the impacts of modulating ""danger-levels"" in immune cell ingestion and activation processes. Looking forward, I hope this research will improve patient outcomes and culminate in an off-the-shelf cancer vaccine.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tseng, Chung Yi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~